GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Chordate Medical Holding AB (OSTO:CMH) » Definitions » ROE %

Chordate Medical Holding AB (OSTO:CMH) ROE % : -112.43% (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Chordate Medical Holding AB ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Chordate Medical Holding AB's annualized net income for the quarter that ended in Mar. 2024 was kr-24.08 Mil. Chordate Medical Holding AB's average Total Stockholders Equity over the quarter that ended in Mar. 2024 was kr21.42 Mil. Therefore, Chordate Medical Holding AB's annualized ROE % for the quarter that ended in Mar. 2024 was -112.43%.

The historical rank and industry rank for Chordate Medical Holding AB's ROE % or its related term are showing as below:

OSTO:CMH' s ROE % Range Over the Past 10 Years
Min: -223.78   Med: -107.91   Max: -42
Current: -104.39

During the past 9 years, Chordate Medical Holding AB's highest ROE % was -42.00%. The lowest was -223.78%. And the median was -107.91%.

OSTO:CMH's ROE % is ranked worse than
87.27% of 801 companies
in the Medical Devices & Instruments industry
Industry Median: -0.63 vs OSTO:CMH: -104.39

Chordate Medical Holding AB ROE % Historical Data

The historical data trend for Chordate Medical Holding AB's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chordate Medical Holding AB ROE % Chart

Chordate Medical Holding AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial Premium Member Only -223.78 -107.91 -67.40 -111.72 -223.14

Chordate Medical Holding AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -118.55 -87.33 -72.09 -196.78 -112.43

Competitive Comparison of Chordate Medical Holding AB's ROE %

For the Medical Devices subindustry, Chordate Medical Holding AB's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chordate Medical Holding AB's ROE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Chordate Medical Holding AB's ROE % distribution charts can be found below:

* The bar in red indicates where Chordate Medical Holding AB's ROE % falls into.



Chordate Medical Holding AB ROE % Calculation

Chordate Medical Holding AB's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-29.187/( (11.073+15.087)/ 2 )
=-29.187/13.08
=-223.14 %

Chordate Medical Holding AB's annualized ROE % for the quarter that ended in Mar. 2024 is calculated as

ROE %=Net Income (Q: Mar. 2024 )/( (Total Stockholders Equity (Q: Dec. 2023 )+Total Stockholders Equity (Q: Mar. 2024 ))/ count )
=-24.076/( (15.087+27.743)/ 2 )
=-24.076/21.415
=-112.43 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2024) net income data. ROE % is displayed in the 30-year financial page.


Chordate Medical Holding AB  (OSTO:CMH) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-24.076/21.415
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-24.076 / 1.032)*(1.032 / 28.218)*(28.218 / 21.415)
=Net Margin %*Asset Turnover*Equity Multiplier
=-2332.95 %*0.0366*1.3177
=ROA %*Equity Multiplier
=-85.39 %*1.3177
=-112.43 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-24.076/21.415
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-24.076 / -24.076) * (-24.076 / -24.132) * (-24.132 / 1.032) * (1.032 / 28.218) * (28.218 / 21.415)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 0.9977 * -2338.37 % * 0.0366 * 1.3177
=-112.43 %

Note: The net income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Chordate Medical Holding AB ROE % Related Terms

Thank you for viewing the detailed overview of Chordate Medical Holding AB's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Chordate Medical Holding AB (OSTO:CMH) Business Description

Traded in Other Exchanges
Address
c/o Regus, Kistagangen 20B, Kista, SWE, 164 40
Chordate Medical Holding AB is a medical technology company that has developed and patented and CE-marked a new nerve-modulating treatment technology for chronic nasal congestion and chronic migraine. The company sells its products in Selected European markets, Israel and Saudi Arabia. The company's product range is based on the CE-marked treatment units Chordate System S100 and S120 for rhinitis and S220 for migraine, registered for the indications of preventive treatment of chronic migraine and chronic rhinitis and use on patients who are 18 years old or older. The company sells its product system, including treatments, through distributors to clinics and hospitals in its primary markets.

Chordate Medical Holding AB (OSTO:CMH) Headlines

No Headlines